Home LiteratureArticle Details
PMID: 23725621 Published · ppublish English Letter Comment

Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time.

American journal of respiratory and critical care medicine ·Vol. 187 ·No. 11 ·2013-06-01 ·Pages 1271-2

Spagnolo P, Luppi F, Maher TM, Wuyts WA, Grutters JC

Abstract

暂无摘要

MeSH Terms
Clinical Trials, Phase III as Topic/methods Endpoint Determination/methods Humans Idiopathic Pulmonary Fibrosis/drug therapy Respiratory System Agents/therapeutic use
Chemicals
Respiratory System Agents
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Spagnolo Paolo
Luppi Fabrizio
Maher Toby M
Wuyts Wim A
Grutters Jan C
Article Info
Journal
American journal of respiratory and critical care medicine
Abbr.
Am J Respir Crit Care Med
ISSN
1535-4970
DOI
10.1164/rccm.201209-1755LE
Published
2013-06-01
Pages
1271-2
Language
English
Region
United States
NLM ID
9421642
Subset
IM
Corrections
CommentOn
PMID: 22505745
CommentIn
PMID: 23725623
External Links
PubMed source DOI: 10.1164/rccm.201209-1755LE View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2